Efficacy and Safety of Celecoxib in Chinese Patients with Ankylosing Spondylitis: A 6-Week Randomized, Double-Blinded Study with 6-Week Open-Label Extension Treatment

Background: Nonsteroidal anti-inflammatory drugs are the first-line option for treating ankylosing spondylitis (AS) in China. However, no large-scale controlled trials have been conducted in this ethnic population. Objective: To evaluate the efficacy and safety of 6 weeks’ treatment with celecoxib i...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Feng Huang, MD, Jieruo Gu, MD, Yi Liu, MD, Ping Zhu, MD, Yi Zheng, MD, Jin Fu, MD, Sharon Pan, PhD, Shi Le, MD
Format:	Artigo
Jezik:	Inglês
Izdano:	Elsevier 2014-12-01
Serija:	Current Therapeutic Research
Teme:	ankylosing spondylitis COX-2 inhibitors musculoskeletal system nonsteroidal anti-inflammatory drugs
Online dostop:	http://www.sciencedirect.com/science/article/pii/S0011393X14000198
Oznake:	Označite Brez oznak, prvi označite!